Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TAZEMETOSTAT HYDROBROMIDE for Bladder cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where TAZEMETOSTAT HYDROBROMIDE was used for Bladder cancer.

Most Reported Side Effects for TAZEMETOSTAT HYDROBROMIDE

Side Effect Reports % Deaths Hosp.
Off label use 298 22.5% 60 48
Fatigue 292 22.1% 10 41
Disease progression 267 20.2% 44 44
Nausea 207 15.7% 12 31
Product dose omission issue 183 13.8% 4 32
Death 106 8.0% 105 27
Diarrhoea 100 7.6% 2 11
Decreased appetite 81 6.1% 4 17
Asthenia 75 5.7% 5 29
Vomiting 75 5.7% 8 16
Constipation 66 5.0% 2 5
Covid-19 65 4.9% 4 30
Alopecia 61 4.6% 2 8
Headache 61 4.6% 3 5
Pain 58 4.4% 5 17

Other Indications for TAZEMETOSTAT HYDROBROMIDE

Follicular lymphoma (439) Soft tissue sarcoma (298) Off label use (102) B-cell lymphoma (91) Malignant connective tissue neoplasm (72) Product used for unknown indication (54) Epithelioid sarcoma (46) Follicular lymphoma stage ii (38) Follicular lymphoma stage i (34) Brain neoplasm malignant (31)

Other Drugs Used for Bladder cancer

BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (1,279) PEMBROLIZUMAB (869) GEMCITABINE (841) CISPLATIN (780) ENFORTUMAB VEDOTIN-EJFV (530) NIVOLUMAB (512) ATEZOLIZUMAB (487) CARBOPLATIN (332) BACILLUS CALMETTE-GUERIN ANTIGEN, UNSPECIFIED SUBSTRAIN (326) GEMCITABINE\GEMCITABINE (240)

Related Pages

TAZEMETOSTAT HYDROBROMIDE Full Profile All Bladder cancer Drugs TAZEMETOSTAT HYDROBROMIDE Demographics TAZEMETOSTAT HYDROBROMIDE Timeline